Shin Poong Pharm.Co.,Ltd. (019170.KS)
KRW 10370.0
(-5.04%)
KRW 10370.0
(-5.04%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 2.35 Billion KRW | 105.91% |
| 2022 | -39.76 Billion KRW | -50.3% |
| 2021 | -26.45 Billion KRW | 51.02% |
| 2020 | -54.01 Billion KRW | -164.99% |
| 2019 | 83.11 Billion KRW | 18.28% |
| 2018 | 70.27 Billion KRW | -24.56% |
| 2017 | 93.14 Billion KRW | -11.58% |
| 2016 | 105.34 Billion KRW | -26.55% |
| 2015 | 143.42 Billion KRW | -5.03% |
| 2014 | 151.01 Billion KRW | 12.32% |
| 2013 | 134.45 Billion KRW | 6.49% |
| 2012 | 126.26 Billion KRW | -6.8% |
| 2011 | 135.47 Billion KRW | 9.99% |
| 2010 | 123.16 Billion KRW | 6.01% |
| 2009 | 116.18 Billion KRW | 20.69% |
| 2008 | 96.26 Billion KRW | 51.13% |
| 2007 | 63.69 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -1.32 Billion KRW | -156.15% |
| 2024 Q2 | -2.71 Billion KRW | -105.93% |
| 2023 Q1 | -17.57 Billion KRW | 55.8% |
| 2023 Q3 | -12.44 Billion KRW | 25.71% |
| 2023 FY | 2.35 Billion KRW | 105.91% |
| 2023 Q2 | -16.75 Billion KRW | 4.65% |
| 2023 Q4 | 2.35 Billion KRW | 118.89% |
| 2022 Q2 | -31.29 Billion KRW | -9.62% |
| 2022 Q4 | -39.76 Billion KRW | -10.21% |
| 2022 FY | -39.76 Billion KRW | -50.3% |
| 2022 Q1 | -28.55 Billion KRW | -7.92% |
| 2022 Q3 | -36.07 Billion KRW | -15.27% |
| 2021 Q4 | -26.45 Billion KRW | 47.37% |
| 2021 Q1 | -62.31 Billion KRW | -15.37% |
| 2021 Q2 | -43.04 Billion KRW | 30.93% |
| 2021 FY | -26.45 Billion KRW | 51.02% |
| 2021 Q3 | -50.26 Billion KRW | -16.78% |
| 2020 Q3 | -138.16 Billion KRW | -273.63% |
| 2020 Q2 | 79.57 Billion KRW | 0.04% |
| 2020 Q1 | 79.54 Billion KRW | -4.3% |
| 2020 FY | -54.01 Billion KRW | -164.99% |
| 2020 Q4 | -54.01 Billion KRW | 60.9% |
| 2019 Q1 | 74.58 Billion KRW | 6.14% |
| 2019 FY | 83.11 Billion KRW | 18.28% |
| 2019 Q4 | 83.11 Billion KRW | -2.15% |
| 2019 Q3 | 84.94 Billion KRW | 5.24% |
| 2019 Q2 | 80.71 Billion KRW | 8.22% |
| 2018 Q2 | 85.69 Billion KRW | 0.81% |
| 2018 Q4 | 70.27 Billion KRW | -13.88% |
| 2018 Q3 | 81.59 Billion KRW | -4.79% |
| 2018 FY | 70.27 Billion KRW | -24.56% |
| 2018 Q1 | 85 Billion KRW | -8.73% |
| 2017 Q3 | 93.2 Billion KRW | -4.17% |
| 2017 Q1 | 99.7 Billion KRW | -5.35% |
| 2017 FY | 93.14 Billion KRW | -11.58% |
| 2017 Q4 | 93.14 Billion KRW | -0.07% |
| 2017 Q2 | 97.27 Billion KRW | -2.44% |
| 2016 FY | 105.34 Billion KRW | -26.55% |
| 2016 Q3 | 110.33 Billion KRW | -1.15% |
| 2016 Q4 | 105.34 Billion KRW | -4.53% |
| 2016 Q2 | 111.61 Billion KRW | -22.28% |
| 2016 Q1 | 143.6 Billion KRW | 0.13% |
| 2015 Q3 | 148.51 Billion KRW | -0.19% |
| 2015 Q1 | 144.54 Billion KRW | -4.29% |
| 2015 FY | 143.42 Billion KRW | -5.03% |
| 2015 Q4 | 143.42 Billion KRW | -3.43% |
| 2015 Q2 | 148.79 Billion KRW | 2.95% |
| 2014 FY | 151.01 Billion KRW | 12.32% |
| 2014 Q3 | 143.52 Billion KRW | 2.19% |
| 2014 Q4 | 151.01 Billion KRW | 5.22% |
| 2014 Q2 | 140.45 Billion KRW | 0.71% |
| 2014 Q1 | 139.45 Billion KRW | 3.72% |
| 2013 Q1 | 124.5 Billion KRW | -1.39% |
| 2013 Q4 | 134.45 Billion KRW | -1.75% |
| 2013 FY | 134.45 Billion KRW | 6.49% |
| 2013 Q2 | 138.12 Billion KRW | 10.94% |
| 2013 Q3 | 136.85 Billion KRW | -0.92% |
| 2012 Q1 | 127.82 Billion KRW | 0.0% |
| 2012 Q4 | 126.26 Billion KRW | 0.0% |
| 2012 FY | 126.26 Billion KRW | -6.8% |
| 2011 Q2 | 133.13 Billion KRW | 0.63% |
| 2011 FY | 135.47 Billion KRW | 9.99% |
| 2011 Q3 | 137.58 Billion KRW | 3.34% |
| 2011 Q1 | 132.29 Billion KRW | 0.0% |
| 2010 Q2 | 121.55 Billion KRW | 3.94% |
| 2010 FY | 123.16 Billion KRW | 6.01% |
| 2010 Q3 | 116.98 Billion KRW | -3.76% |
| 2010 Q1 | 116.94 Billion KRW | 0.0% |
| 2009 Q2 | 109.3 Billion KRW | 4.82% |
| 2009 FY | 116.18 Billion KRW | 20.69% |
| 2009 Q3 | 114.06 Billion KRW | 4.36% |
| 2009 Q1 | 104.27 Billion KRW | 0.0% |
| 2008 FY | 96.26 Billion KRW | 51.13% |
| 2008 Q2 | 78.2 Billion KRW | 8.85% |
| 2008 Q1 | 71.85 Billion KRW | 0.0% |
| 2008 Q3 | 89.53 Billion KRW | 14.49% |
| 2007 Q2 | 57.68 Billion KRW | 12.81% |
| 2007 Q3 | 58.03 Billion KRW | 0.61% |
| 2007 FY | 63.69 Billion KRW | 0.0% |
| 2007 Q1 | 51.13 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 8.8 Billion KRW | 73.287% |
| Dong-A Socio Holdings Co., Ltd. | 572.02 Billion KRW | 99.589% |
| Ildong Holdings Co., Ltd. | 310.87 Billion KRW | 99.244% |
| HANDOK Inc. | 283.45 Billion KRW | 99.17% |
| Kukje Pharma Co., Ltd. | 20.07 Billion KRW | 88.286% |
| Yuhan Corporation | -69.18 Billion KRW | 103.399% |
| Dong-A ST Co., Ltd. | 193.95 Billion KRW | 98.788% |
| SAMSUNG PHARM. Co., LTD. | -3.68 Billion KRW | 163.794% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | 99.546% |
| Hanall Biopharma Co.,Ltd | -32.43 Billion KRW | 107.25% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 96.893% |
| Dong Sung Bio Pharm.Co.,Ltd. | 36.83 Billion KRW | 93.617% |
| MYUNGMOON Pharm co.,Ltd | 82.52 Billion KRW | 97.151% |
| Hana Pharm Co., Ltd. | 25.1 Billion KRW | 90.635% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | 73.287% |
| Ilsung Pharmaceuticals Co., Ltd. | -159.84 Billion KRW | 101.471% |
| REYON Pharmaceutical Co., Ltd. | 200.94 Billion KRW | 98.83% |
| Aprogen pharmaceuticals,Inc. | 170.94 Billion KRW | 98.625% |
| JW Holdings Corporation | 480.68 Billion KRW | 99.511% |
| Ildong Pharmaceutical Co., Ltd. | 164.58 Billion KRW | 98.571% |
| Chong Kun Dang Pharmaceutical Corp. | 117.53 Million KRW | -1900.587% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 98.477% |
| Hyundai Pharmaceutical Co., Ltd. | 23 Billion KRW | 89.778% |
| Samil Pharmaceutical Co.,Ltd | 174.97 Billion KRW | 98.656% |
| Jeil Pharmaceutical Co.,Ltd | 51.97 Billion KRW | 95.476% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | 73.287% |
| Kwang Dong Pharmaceutical Co., Ltd. | 158.29 Billion KRW | 98.515% |
| Daewoong pharmaceutical Co.,Ltd | 358.17 Billion KRW | 99.344% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 98.477% |
| Yuhan Corporation | -69.18 Billion KRW | 103.399% |
| Jeil Pharma Holdings Inc | 135.99 Billion KRW | 98.271% |
| Yungjin Pharm. Co., Ltd. | 59.67 Billion KRW | 96.06% |
| Suheung Co., Ltd. | 429.14 Billion KRW | 99.452% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 98.477% |
| Samjin Pharmaceuticals Co., Ltd. | 116.23 Billion KRW | 97.977% |
| Korea United Pharm Inc. | 16.42 Billion KRW | 85.685% |
| CKD Bio Corp. | 143.29 Billion KRW | 98.359% |
| Daewon Pharmaceutical Co., Ltd. | 116.06 Billion KRW | 97.974% |
| Dongwha Pharm.Co.,Ltd | -24.06 Billion KRW | 109.772% |
| Whan In Pharm Co.,Ltd. | -44.73 Billion KRW | 105.256% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | 0.0% |
| Chong Kun Dang Holdings Corp. | 422.84 Billion KRW | 99.444% |
| Boryung Corporation | 187.72 Billion KRW | 98.747% |
| Bukwang Pharmaceutical Co., Ltd. | -71.84 Billion KRW | 103.273% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 96.893% |
| JW Lifescience Corporation | 26.09 Billion KRW | 90.988% |